FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316642208> ?p ?o ?g. }

• W2316642208 endingPage "71" @default.
• W2316642208 startingPage "65" @default.
• W2316642208 abstract "Oxidized low-density lipoprotein (Ox-LDL) is believed to play an important role in the progression of atherosclerosis. Oxidative modification of low-density lipoprotein (LDL) is a prerequisite for rapid accumulation of LDL in macrophages and for the formation of foam cells. Because of high antioxidant levels in plasma, LDL oxidation is suggested to occur mainly in the subendothelial space of the arterial wall, where there is the concomitant presence of large amounts of reactive oxygen species generated by endothelial cells and activated leukocytes. After Ox-LDL formation, antibodies against this form of LDL may occur. Auto-antibodies against Ox-LDL (AuAb-Ox-LDL) show directly in in-vivo LDL oxidation. Many studies have indicated that the amount of antibodies in serum is positively correlated to the rate of progression of atherosclerotic plaques.In this study the effect of lipid-lowering therapy on the levels of AuAb-Ox-LDL in patients with dyslipidemia was determined using atorvastatin (10 mg/day), and the relationship between the antibodies and plasma total antioxidant status (TAS) and LDL oxidation capacity was also investigated. Serum levels of AuAb-Ox-LDL, lipids, lipoproteins, TAS and susceptibility of LDL to oxidation were determined using lag time in 44 patients with dyslipidemia (29 with hypercholesterolemia and 15 with mixed-type hyperlipidemia).After lipid-lowering therapy, serum levels of AuAb-Ox-LDL were found to be significantly decreased, by 18.7%, while lag time and plasma TAS were increased (31.3% and 7.6% respectively) in patients with dyslipidemia. The percentage change in lag time was found to be negatively correlated to the percentage change in AuAb-Ox-LDL (r = -0.31, P < 0.05). The percentage change in lag time also showed a positive correlation with the percentage change in TAS (r = 0.58, P < 0.01). AuAb-Ox-LDL levels decreased by 21.7% in patients with hypercholesterolemia and by 12.6% in patients with mixed-type hyperlipidemia. Also AuAb-Ox-LDL levels in patients with hypercholesterolemia were higher than in those with mixed-type hyperlipidemia (367 +/- 294 compared with 300 +/- 176 mU/l).It was concluded that lipid-lowering therapy may contribute to the reduction in levels of AuAb-Ox-LDL and the increase in the antioxidant capacity of plasma LDL and TAS. It was also suggested that the measurement of antibodies against Ox-LDL during lipid-lowering therapy may be used as an important marker for representing in-vivo LDL oxidation and atherosclerotic processes." @default.
• W2316642208 created "2016-06-24" @default.
• W2316642208 creator A5004663975 @default.
• W2316642208 creator A5016535638 @default.
• W2316642208 creator A5055323715 @default.
• W2316642208 creator A5075360721 @default.
• W2316642208 creator A5089513956 @default.
• W2316642208 creator A5089775439 @default.
• W2316642208 date "2002-02-01" @default.
• W2316642208 modified "2023-09-26" @default.
• W2316642208 title "The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status" @default.
• W2316642208 cites W1254756 @default.
• W2316642208 cites W1775749144 @default.
• W2316642208 cites W1961179371 @default.
• W2316642208 cites W1968679020 @default.
• W2316642208 cites W1979655335 @default.
• W2316642208 cites W1984526039 @default.
• W2316642208 cites W1988474098 @default.
• W2316642208 cites W1994780120 @default.
• W2316642208 cites W1997704936 @default.
• W2316642208 cites W1998165066 @default.
• W2316642208 cites W2003842402 @default.
• W2316642208 cites W2008457386 @default.
• W2316642208 cites W2014820285 @default.
• W2316642208 cites W2026486766 @default.
• W2316642208 cites W2028283951 @default.
• W2316642208 cites W2031550562 @default.
• W2316642208 cites W2044905377 @default.
• W2316642208 cites W2052497105 @default.
• W2316642208 cites W2060485980 @default.
• W2316642208 cites W2067310352 @default.
• W2316642208 cites W2080290793 @default.
• W2316642208 cites W2088811446 @default.
• W2316642208 cites W2092575109 @default.
• W2316642208 cites W2092699838 @default.
• W2316642208 cites W2111551082 @default.
• W2316642208 cites W2129750583 @default.
• W2316642208 cites W2131275408 @default.
• W2316642208 cites W2143833093 @default.
• W2316642208 cites W2155598961 @default.
• W2316642208 cites W2159506419 @default.
• W2316642208 cites W2212323528 @default.
• W2316642208 cites W2339031854 @default.
• W2316642208 cites W3022864527 @default.
• W2316642208 doi "https://doi.org/10.1097/00019501-200202000-00009" @default.
• W2316642208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11917201" @default.
• W2316642208 hasPublicationYear "2002" @default.
• W2316642208 type Work @default.
• W2316642208 sameAs 2316642208 @default.
• W2316642208 citedByCount "37" @default.
• W2316642208 countsByYear W23166422082012 @default.
• W2316642208 countsByYear W23166422082013 @default.
• W2316642208 countsByYear W23166422082014 @default.
• W2316642208 crossrefType "journal-article" @default.
• W2316642208 hasAuthorship W2316642208A5004663975 @default.
• W2316642208 hasAuthorship W2316642208A5016535638 @default.
• W2316642208 hasAuthorship W2316642208A5055323715 @default.
• W2316642208 hasAuthorship W2316642208A5075360721 @default.
• W2316642208 hasAuthorship W2316642208A5089513956 @default.
• W2316642208 hasAuthorship W2316642208A5089775439 @default.
• W2316642208 hasConcept C126322002 @default.
• W2316642208 hasConcept C134018914 @default.
• W2316642208 hasConcept C159654299 @default.
• W2316642208 hasConcept C185592680 @default.
• W2316642208 hasConcept C203014093 @default.
• W2316642208 hasConcept C2777482532 @default.
• W2316642208 hasConcept C2778004101 @default.
• W2316642208 hasConcept C2778096610 @default.
• W2316642208 hasConcept C2778163477 @default.
• W2316642208 hasConcept C2779091943 @default.
• W2316642208 hasConcept C2779620165 @default.
• W2316642208 hasConcept C2780072125 @default.
• W2316642208 hasConcept C43554185 @default.
• W2316642208 hasConcept C511355011 @default.
• W2316642208 hasConcept C55493867 @default.
• W2316642208 hasConcept C555293320 @default.
• W2316642208 hasConcept C71924100 @default.
• W2316642208 hasConceptScore W2316642208C126322002 @default.
• W2316642208 hasConceptScore W2316642208C134018914 @default.
• W2316642208 hasConceptScore W2316642208C159654299 @default.
• W2316642208 hasConceptScore W2316642208C185592680 @default.
• W2316642208 hasConceptScore W2316642208C203014093 @default.
• W2316642208 hasConceptScore W2316642208C2777482532 @default.
• W2316642208 hasConceptScore W2316642208C2778004101 @default.
• W2316642208 hasConceptScore W2316642208C2778096610 @default.
• W2316642208 hasConceptScore W2316642208C2778163477 @default.
• W2316642208 hasConceptScore W2316642208C2779091943 @default.
• W2316642208 hasConceptScore W2316642208C2779620165 @default.
• W2316642208 hasConceptScore W2316642208C2780072125 @default.
• W2316642208 hasConceptScore W2316642208C43554185 @default.
• W2316642208 hasConceptScore W2316642208C511355011 @default.
• W2316642208 hasConceptScore W2316642208C55493867 @default.
• W2316642208 hasConceptScore W2316642208C555293320 @default.
• W2316642208 hasConceptScore W2316642208C71924100 @default.
• W2316642208 hasIssue "1" @default.
• W2316642208 hasLocation W23166422081 @default.
• W2316642208 hasLocation W23166422082 @default.
• W2316642208 hasOpenAccess W2316642208 @default.

• next